GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Jul 2017 03:30 PM
RNS
Director/PDMR Shareholding
21 Jul 2017 01:59 PM
RNS
GSK submits EU filing for Relvar Ellipta extension
21 Jul 2017 11:00 AM
RNS
Directorate Change
17 Jul 2017 06:08 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 05:44 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 05:37 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 05:19 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 04:53 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 04:37 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 02:20 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 04:58 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 04:46 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 04:02 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 11:57 AM
RNS
Director/PDMR Shareholding
12 Jul 2017 04:12 PM
RNS
Director/PDMR Shareholding
03 Jul 2017 10:05 AM
RNS
Total Voting Rights
28 Jun 2017 04:13 PM
RNS
GSK announces US filing for mepo in EGPA
27 Jun 2017 10:06 AM
RNS
GSK starts phIII study on mepo for nasal polyps
21 Jun 2017 02:35 PM
RNS
Director/PDMR Shareholding
21 Jun 2017 02:05 PM
RNS
GSK presents Shingrix PhIII study results at ACIP
19 Jun 2017 04:29 PM
RNS
GSK confirms start date for Luke Miels
12 Jun 2017 04:43 PM
RNS
Director/PDMR Shareholding
05 Jun 2017 05:23 PM
RNS
Director/PDMR Shareholding
02 Jun 2017 07:00 AM
RNS
ViiV submits first 2-drug HIV regimen application
01 Jun 2017 10:58 AM
RNS
Total Voting Rights
31 May 2017 04:25 PM
RNS
Director/PDMR Shareholding
22 May 2017 04:45 PM
RNS
Director/PDMR Shareholding
22 May 2017 04:40 PM
RNS
Director/PDMR Shareholding
22 May 2017 02:23 PM
RNS
Ph3 MUSCA study presented at ATS
18 May 2017 07:00 AM
RNS
NEJM publication of PH3 study into Mepo in EGPA
12 May 2017 04:26 PM
RNS
Block listing Interim Review
11 May 2017 05:29 PM
RNS
Director/PDMR Shareholding
10 May 2017 04:26 PM
RNS
Headline Phase III results: Mepo in COPD
05 May 2017 12:39 PM
RNS
Rellvar Ellipta 2nd Salford Lung Study Results
04 May 2017 06:10 PM
RNS
Result of AGM
02 May 2017 01:02 PM
RNS
Director/PDMR Shareholding
02 May 2017 10:02 AM
RNS
Total Voting Rights
27 Apr 2017 05:40 PM
RNS
Director/PDMR Shareholding
27 Apr 2017 04:53 PM
RNS
Companies Act 2006 s430 (2B) Disclosure
26 Apr 2017 05:25 PM
RNS
Indenture 2004 - change of trustee
26 Apr 2017 12:00 PM
RNS
1st Quarter Results
25 Apr 2017 05:24 PM
RNS
Director/PDMR Shareholding
25 Apr 2017 01:45 PM
RNS
Director/PDMR Shareholding
24 Apr 2017 04:52 PM
RNS
Director/PDMR Shareholding replacement
21 Apr 2017 02:49 PM
RNS
Director/PDMR Shareholding
21 Apr 2017 01:36 PM
RNS
Director/PDMR Shareholding
19 Apr 2017 05:38 PM
RNS
Director/PDMR Shareholding
19 Apr 2017 04:34 PM
RNS
Director/PDMR Shareholding
19 Apr 2017 04:27 PM
RNS
Director/PDMR Shareholding
19 Apr 2017 04:14 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings